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Abstract. 11 
Whooping cough, or pertussis, caused by Bordetella pertussis is considered 12 
resurgent in a number of countries world-wide, despite continued high level 13 
vaccine coverage. Among a number of causes for this that have been 14 
proposed, is the emergence of B. pertussis strains expressing variants of the 15 
antigens contained in acellular pertussis vaccines; i.e. the evolution of B. 16 
pertussis towards vaccine escape. This commentary highlights the 17 
contradictory nature of evidence for this but also discusses the importance of 18 
understanding the role of B. pertussis adaptation to vaccine-mediated immune 19 
selection pressures for vaccine-mediated pertussis control strategies. 20 
 21 
Resurgence. 22 
Whooping cough, or pertussis, caused by Bordetella pertussis is considered 23 
resurgent in a number of countries despite high levels of vaccination of infants 24 
in these regions. 1 This has involved an increase in the overall number of 25 
 2 
cases diagnosed and also a clear increase in disease incidence in older 26 
children and adults suggesting a changing epidemiology of pertussis. 27 
 28 
Explanations for this recent rise in disease incidence have been reviewed 29 
extensively during the last few years (for example, see ref. 2) but briefly, a 30 
switch from the use of a whole cell pertussis vaccine (WCV) to an acellular 31 
one (ACV) appears to be a key factor. In humans, the duration of protective 32 
immunity afforded by the ACV appears to be shorter than that arising from 33 
use of the WCV. 3-5 It has been long recognised that while WCVs induce a 34 
mainly Th1 biased response, the response to ACVs has a distinct Th2 bias. 6 35 
Using an infant baboon model of pertussis, there are clear differences 36 
between WCV- and ACV-induced immunity. Both types of vaccines protect 37 
the individual against disease but animals vaccinated with ACV were 38 
colonised to a higher level and for longer when subsequently challenged with 39 
B. pertussis, compared to animals vaccinated with WCV. 7 Interestingly, 40 
vaccine-induced immunity, either from WCV or ACV, was inferior to immunity 41 
arising from natural infection in terms of protecting against colonisation 42 
following subsequent challenge. 7 Thus, it is very likely that the switch to the 43 
use of an ACV has changed the epidemiology of pertussis, resulting in the 44 
changing disease patterns observed. 45 
 46 
This has led to debate about the need for novel pertussis vaccines, 47 
particularly one that induces sterilising immunity. 8 However, there is no clear 48 
pathway to testing or licensing such vaccines. It may be possible to introduce 49 
novel vaccines as boosters for adolescents and adults but there are major 50 
 3 
obstacles to implementing novel vaccines for infant immunisation while the 51 
current ones do provide significant protection to infants against disease. 52 
 53 
Evolution towards vaccine escape. 54 
Also implicated in resurgence is the evolution of B. pertussis such that current 55 
strains are less susceptible to vaccine-induced immunity compared to older 56 
strains, i.e. B. pertussis is evolving towards vaccine escape. 9, 10 There is a 57 
clear rationale for why this might happen. The WCV presents a wide range of 58 
antigens to the immune system, compared to the 5-9 B. pertussis proteins 59 
that comprise ACVs. Thus, ACV-induced immunity is focused on just a few 60 
proteins, creating a stronger selection pressure for strains expressing 61 
antigenic variants of these proteins. Genomic analyses of B. pertussis has 62 
revealed that recent evolution of these bacteria has involved selective sweeps 63 
in which a novel vaccine antigen allele arises and largely replaces the 64 
previous dominant allele in the B. pertussis population, suggestive of a fitness 65 
advantage conferred by the new allele, for example see refs. 11-13 66 
 67 
In particular, regions experiencing resurgence have reported a dramatic rise 68 
in the frequency of strains that are deficient in the expression of Pertactin 69 
(Prn), one of the antigens included in ACVs. Clearly such strains are able to 70 
cause pertussis, but several lines of evidence suggest that they have a 71 
selective advantage over Prn-expressing strains in vaccinated hosts. 72 
 73 
For example, vaccinated people appear more likely to be infected by a Prn-74 
deficient strain than one expressing pertactin, as determined by analysis of 75 
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cases in the US where there is high coverage with ACVs. 14 Using the mouse 76 
model of B. pertussis infection it was demonstrated that naïve mice were 77 
colonized to the same level by Prn-expressing or Prn-deficient strains. 78 
However, in mice immunized with ACV and then subsequently challenged 79 
with B. pertussis, Prn-expressing strains were cleared more quickly than Prn-80 
deficient ones. 15 Finally, a very recent study developed this further and 81 
assessed direct competition between Prn-expressing and Prn-deficient strains 82 
in the murine infection model. 16 Coinfection of naïve mice and ACV-83 
immunised mice with equal numbers of a Prn-expressing and a Prn-deficient 84 
strain revealed dramatic differences. In naïve mice the Prn-expressing strain 85 
became dominant by day 3 post-inoculation and accounted for over 90% of 86 
the B. pertussis recovered by day 14, demonstrating a distinct fitness 87 
advantage from expression of Prn in these hosts. However, in immunized 88 
mice, the reverse was observed, as the Prn-deficient strain accounted for over 89 
90% of recovered bacteria by day 14. 16 Together these data very strongly 90 
suggest that the loss of expression of Prn generates a fitness advantage to B. 91 
pertussis, but only in hosts immunized with an ACV. This is compelling 92 
evidence to suggest that ACV-induced immunity generates a strong selection 93 
pressure on B. pertussis and in turn this suggests that this selection pressure 94 
has been the driver for the emergence of Prn-deficient B. pertussis strains. 95 
 96 
That Prn-deficient strains are isolated from people displaying disease 97 
symptoms demonstrates that Pertactin is not required by B. pertussis for 98 
either colonisation of, or pathogenesis in, humans; enabling survival of these 99 
strains. If avoidance of immunity is the driver for loss of Prn-expression, then 100 
 5 
it might be expected that this would select also for B. pertussis strains 101 
expressing antigenically variant Prn. Although a number of prn alleles have 102 
been identified, variation occurs primarily through variability in the number of 103 
repeat motifs within the gene, as opposed to mutations altering the amino acid 104 
sequence of Prn, discussed in ref. 9 This could be explained by a polyclonal 105 
immune response against Prn, targeting multiple regions of the protein. In this 106 
case, small changes in protein sequence such as single amino acid 107 
substitutions arising from SNPs are unlikely to have much effect on avoidance 108 
of this immunity. Data regarding epitopes on B. pertussis proteins that are 109 
recognised by vaccine-induced immunity is limited. 17 In particular, clear 110 
correlates of protection have not been defined and thus it is not possible to 111 
identify specific epitopes whose recognition is pivotal for protective immunity 112 
that would be expected to exert strong selective pressure. However, current 113 
data does support the idea that responses are polyclonal. 114 
 115 
This might explain also why the level of variation in vaccine antigen genes, 116 
aside from the issue of pertactin-deficiency, among thousands of B. pertussis 117 
strains analysed, is very low (for example, see refs. 11, 18) To our knowledge, 118 
only 10 ptxA alleles, (encoding the PtxA subunit of pertussis toxin, another 119 
ACV component) have been described, mostly involving just one or two 120 
mutations, and two of which carried synonomous mutations. Thus, there are 121 
just 8 protein variants observed in many, many strains isolated world-wide 122 
over many decades. In addition, it is clear that a single allele has dominated 123 
at any one time. For example, numerous studies since suggest that since 124 
2000, well over 90% of isolates carry the ptxA1 allele indicating that there has 125 
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been very little protein variation in PtxA among B. pertussis during this time 126 
(for example, see refs. 11, 18) 127 
 128 
Interestingly, although few, several PtxA polymorphisms occur in regions that 129 
are thought to be B or T cell epitopes 17 but there is no data as to whether any 130 
of the polymorphisms result in altered recognition by cells of the immune 131 
system. 132 
 133 
 A similarly very low level of variation is observed for the other ACV antigens 134 
(again, for example see refs. 11, 18). Thus it is not clear why an apparently 135 
strong selection pressure on Prn is not apparent for the other ACV antigens. 136 
There are key differences between these antigens. Pertussis toxin is a 137 
secreted protein complex. Thus, anti-toxin immunity is thought be largely 138 
toxin-neutralising rather than targeting the bacterium but the toxin has a key 139 
role in B. pertussis infection and therefore one would still predict a strong 140 
selection pressure to avoid toxin-neutralising immune responses. The 141 
expression of fimbrial antigens is subject to phase-variation, via variability in 142 
the length of a homopolymeric tract within the fim gene promoters. 19 This 143 
might provide a mechanism for avoiding anti-Fim immunity in the absence of 144 
Fim variation, but if Fim are required for adherence during colonisation and 145 
subsequent infection, it is hard to see how anti-Fim immunity does not create 146 
selection pressure on these proteins. 147 
 148 
Thus, the role of vaccine antigen variation in B. pertussis evolution, or 149 
adaptation to vaccine-mediated immunity is not clear at present. However, it is 150 
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a very important issue. This is true for considerations about increased use of 151 
current ACVs in booster vaccinations in adolescents and adults in response to 152 
resurgence. If increased use of vaccines were to further increase the selective 153 
pressure for variation, this might increase the rate at which strains emerge 154 
that are increasingly mismatched to vaccine-mediated immunity and thus with 155 
greater fitness advantages in immunised hosts. The same is true also if ACVs 156 
are modified. For example, it has been proposed to ‘update’ ACVs by 157 
including antigens from strains that include antigen variants. 158 
 159 
Any development of novel ACVs must also take into account the likely 160 
selective pressures that they may create. Genomics has revealed all of the 161 
potential B. pertussis antigens present in this bacterium. Thus identifying 162 
novel antigens is not difficult. Nor is testing their immunogenicity and the 163 
protective effect of immune responses against infection, particularly with the 164 
availability of an infant baboon model of pertussis. However, just as for 165 
current ACVs, avoiding selection pressures that might create short lifespans 166 
for novel vaccines is critically important.  167 
 168 
Implementing novel B. pertussis vaccines, or even modified versions of 169 
current ACVs, is a major process to undertake, and likely to be possible only 170 
once, or a very limited number of times. Thus it is imperative to understand 171 
the effect of antigen variation on immunity in order to inform this process. 172 
 173 
In turn, this requires a detailed understanding of the mechanisms of protective 174 
immunity against B. pertussis, including whether certain epitopes are key to 175 
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this in terms of ACV induced immunity. A number of groups are now 176 
beginning to identify B and T cell epitopes recognised either during infection 177 
or by vaccine-induced immunity (for example, see refs. 20-22, but knowledge 178 
regarding protection is still lacking. 179 
 180 
In addition, it is important to develop models in which these aspects can be 181 
investigated, and resulting hypotheses tested. To this end, the recently 182 
developed infant baboon model of pertussis will be vital, and two human 183 
challenge models of B. pertussis colonisation are in the process of 184 
development. While these will be invaluable to answering key questions, they 185 
will be limited in terms of the number of studies able to be performed using 186 
them, and the number of subjects within each study. The mouse model of B. 187 
pertussis infection has been much maligned as a tool for investigating 188 
resurgence, but it is the one in vivo model that can be used widely among 189 
research labs and whose ability to use greater numbers of animals than is 190 
possible with baboons provides greater power for detecting slight effects. In 191 
addition, the availability of genetically modified mice provides powerful tools to 192 
investigate the role of specific immune components and processes in 193 
immunity to B. pertussis and provide mechanistic insight. 23 194 
 195 
In summary, the dramatic rise in the incidence of pertactin-deficient B. 196 
pertussis strains in countries using ACVs, and the demonstration of a fitness 197 
advantage of these strains over those expressing pertactin, in immunised 198 
hosts, strongly supports the idea that vaccine-mediated immunity creates a 199 
selective pressure capable of shaping the genetic make up of B. pertussis. 200 
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However, this is in contrast to the very low levels of variation observed for the 201 
other ACV antigens. Thus, the role of variation among B. pertussis in 202 
adaptation to vaccination and thus pertussis resurgence is unclear at present 203 
but important to determine for understanding resurgence, for expanded use of 204 
current ACVs and for the design of novel vaccines to combat B. pertussis.  205 
 206 
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